I1 imidazoline receptors in cardiovascular regulation: The place of rilmenidine

American Journal of Hypertension

Volumn 13, Issue 6 II SUPPL., 2000, Pages

  Head, Geoffrey A ^a   Burke, Sandra L ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

2 adrenoceptors; Central noradrenergic neurons; Idazoxan; Imidazoline receptors; Rilmenidine; Rostral ventrolateral medulla; Sympathetic activity

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA METHYLDOPAMINE; CATECHOLAMINE; CLONIDINE; CORBADRINE; EFAROXAN; IDAZOXAN; IMIDAZOLINE; IMIDAZOLINE I1 RECEPTOR; PHENETHYLAMINE; RILMENIDINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; DRUG RECEPTOR; IMIDAZOLINE I1 RECEPTORS; OXAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BRAIN STEM; CARDIOVASCULAR FUNCTION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY FUNCTION; MEDULLA OBLONGATA; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RABBIT; RAT; STRESS; SYMPATHETIC NERVE; SYMPATHETIC REFLEX; SYMPATHETIC TONE; VAGUS REFLEX; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; PHYSIOLOGY; REVIEW;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR PHYSIOLOGY; HUMANS; OXAZOLES; RECEPTORS, DRUG;

EID: 0034199369     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Hoefke W, Kobinger W: Pharmacological effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride, a new, antihypertensive substance. Arzneimittelforschung 1966;16:1038-1050.
2. Schmitt H, Schmitt-Jubeau H, Daskalopoulos NT: Central mechanisms of clonidine. Trends Pharmacol Sci 1979;4:71-73.
3. Bousquet P, Guertzenstein PG: Localization of the central cardiovascular action of clonidine. Br J Pharmacol 1973;49:573-579.
4. Finch L, Haeusler G: Further evidence for a central hypotensive action of α-methyldopa in both the rat and cat. Br J Pharmacol 1973;47:217-228.
5. Bobik A, Jennings G, Jackman G, Oddie C, Korner P: Evidence for a predominantly central hypotensive effect of alpha-methyldopa in humans. Hypertension 1986;8:16-23.
6. Starke K, Altmann KP: Inhibition of adrenergic neurotransmission by clonidine: an action on prejunctional-receptors. Neuropharmacology 1973;12:339-347.
7. Ruffolo RR, Turowski BS, Patil PN: Lack of cross desensitization between structurally dissimilar alpha-adrenoceptor agonists. J Pharm Pharmacol 1977;29:378-380.
8. Karppanen H, Paakkari I, Paakkari P: Further evidence for central histamine H2-receptor involvement in the hypotensive effect of clonidine in the rat. Eur J Pharmacol 1977;42:299-302.
9. Bousquet P, Feldman J, Bloch R, Schwartz J: The nucleus reticularis lateralis: a region highly sensitive to clonidine. Eur J Pharmacol 1981;69:389-392.
10. Bousquet P, Feldman J, Schwartz J: Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984;230:232-236.
11. 2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 1987;134:1-13.
12. Ernsberger P, Guiliano R, Willette RN, Reis DJ: Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990;253:408-418.
13. Reis DJ, Piletz JE: The imidazoline receptor in control of blood pressure by clonidine and allied drugs. Am J Physiol 1997;42:R1569-R1571.
14. 2-adrenoceptors involved in the sympatho-inhibitory actions of centrally acting antihypertensive agents. J Auton Nerv Syst 1998;72:163-169.
15. 1-imidazoline receptors: an update. J Hypertens 1998;16: S1-S5.
16. Regunathan S, Reis DJ: Imidazoline receptors and their endogenous ligands. Annu Rev Pharmacol Toxic 1996; 36:511-544.
17. 1) receptors and renal mechanisms in relation to their antihypertensive therapeutic potential. Clin Exp Pharmacol Physiol 1996;23:845-854.
18. 1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine. J Hypertens 1997;15:117-125.
19. 1 receptor and the pharmacology of imidazolines. Cardiovasc Drugs Ther 1994;8:21-26.
20. Head GA, Chan CKS, Sannajust F: Role of imidazoline receptors in the central actions of rilmenidine, moxonidine, and clonidine in conscious rabbits. J Hypertens 1994;12:S100.
21. Head GA, Sannajust F: Importance of imidazoline receptors in the cardiovascular responses to clonidine and rilmenidine in conscious rabbits. Fundam Clin Pharmacol 1992;6 (suppl 1):31s-43s.
22. Hamilton CA: The role of imidazoline receptors in blood pressure regulation. Pharmacol Ther 1992;54: 231-248.
23. Tibirica E, Feldman J, Bousquet P: Differences in the ability of yohimbine to antagonize the hypotensive effect of clonidine in normotensive and spontaneously hypertensive anaesthetized rats. J Pharmacol Exp Ther 1988;244:1062-1066.
24. Van Zwieten P, Thoolen MJM, Timmermans PBMWM: The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine. Hypertension 1984;6 (suppl 11):s28-s33.
25. Tibirica E, Feldman J, Mermet C, Monassier L, Gonon F, Bousquet P: Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline-preferring receptors. Eur J Pharmacol 1991;209:213-221.
26. 2-adrenoceptors affect sleep and arousal mechanisms. Br J Pharmacol 1987;90:675-685.
27. Redmond DE Jr, Huang YH: The primate locus coeruleus and effects of clonidine on opiate withdrawal. J Clin Psychiatry 1982;43:25-29.
28. 2-adrenoceptor agonist. J Pharmacol 1985;16:259-278.
29. Van Zwieten PA, Thoolen MJMC, Jonkman FAM, Wilffert B, de Jonge A, Timmermans PBMWM: Central and peripheral effects of S3341 [(N-dicyclopropylmethyl)-amino-2-oxazoline] in animal models. Arch Int Pharmacodyn Ther 1986;279:130-149.
30. 2-adrenoceptor agonist rilmenidine. Am J Cardiol 1988;61 (suppl 7):6D-14D.
31. Bricca G, Dontenwill M, Molines A, Feldman J, Tibirica E, Belcourt A, Bousquet P: Rilmenidine selectivity for imidazoline receptors in human brain. Eur J Pharmacol 1989;163:373-377.
32. Gomez RE, Ernsberger P, Feinland G, Reis DJ: Rilmenidine lowers arterial pressure via imidazole receptors in brainstem Cl area. Eur J Pharmacol 1991;195:181-191.
33. 1-imidazoline receptors. J Cardiovasc Pharmacol 1992;20 (suppl 4):S1-S10.
34. 1-imidazoline sites. J Pharmacol Exp Ther 1993;264:172-182.
35. Ostermann G, Brisgand B, Schmitt J, Fillastre JP: Efficacy and acceptability of rilmenidine for mild to moderate systemic hypertension. Am J Cardiol 1988;61 (suppl 7):76D-80D.
36. Fillastre JP, Letac B, Galinier F, Le Bihan G, Schwartz J: A multicentre double blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am J Cardiol 1988;61 (suppl 7):81D-85D.
37. 1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. J Cardiovasc Pharmacol 1994;24 (suppl l)s:S39-S48.
38. 1 receptor specific agent. J Med Chem 1996;39:1193-1195.
39. Feldman J, Greney H, Monassier L, Vonthron C, Bruban V, Dontenwill M, Bousquet P: Does a second generation of centrally acting antihypertensive drugs really exist? J Auto Nerv Syst 1998;72:94-97.
40. 2A-adrenergic receptor subtype. Science 1996;273:801-803.
41. Guyenet PG: Is the hypotensive effect of clonidine and related drugs due to imidazoline binding sites? Am J Physiol 1997;42:R1580-R1584.
42. 2-Adrenergic receptors rather than "imidazoline" binding sites mediate the sympatholytic effect of clonidine in the rostral ventrolateral medulla: a new look at the evidence, in: Trouth O, Mills R, Kiwull-Schone H, Schlafke ME (eds): Ventral Brainstem Mechanisms and Control Functions. Marcel Dekker Inc., New York, 1995, pp 281-303.
43. 2A-adrenoceptors. Eur J Pharmacol 1989;167:95-104.
44. 1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens 1997;15 (suppl): S9-S23.
45. Sannajust F, Head GA: Rilmenidine-induced hypotension in conscious rabbits involves imidazoline-preferring receptors. J Cardiovasc Pharmacol 1994;23:42-50.
46. Head GA, Godwin SJ, Sannajust F: Differential receptors involved in the cardiovascular effects of clonidine and rilmenidine in conscious rabbits. J Hypertens 1993;11 (suppl 5):S322-S323.
47. Haxhiu MA, Dreshaj I, Schafer SG, Ernsberger P: Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994;24 (suppl 1):S1-S8.
48. Chan CKS, Sannajust F, Head GA: Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. J Pharmacol Exp Ther 1996;276:411-420.
49. Chan CKS, Head GA: Relative importance of central imidazoline receptors for the anti-hypertensive effects of moxonidine and rilmenidine. J Hypertens 1996;14: 855-864.
50. 1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci 1995;763:22-42.
51. Dorward PK, Riedel W, Burke SL, Gipps J, Korner PI: The renal sympathetic baroreflex in the rabbit. Arterial and cardiac baroreceptor influences, resetting, and effect of anesthesia. Circ Res 1985;57:618-633.
52. Radaelli A, Bernardi L, Valle F, Leuzzi S, Salvucci F, Pedrotti L, Maschesi E, Finardi A, Sleight P: Cardiovascular autonomic modulation in essential hypertension. Effect of tilting. Hypertension 1994;24:556-563.
53. Murphy CA, Sloan RP, Myers MM: Pharmacologic responses and spectral analyses of spontaneous fluctuations in heart rate and blood pressure in SHR rats. J Auto Nerv Syst 1991;36:237-250.
54. Cerutti C, Gustin MP, Paultre CZ, Lo M, Julien C, Vincent M, Sassard J: Autonomic nervous system and cardiovascular variability in rats - a spectral analysis approach. Am J Physiol 1991;261:H1292-H1299.
55. Korner PI, Head GA: Baroreflexes in hypertension in Kunos G, Ciriello J (eds): Central Neural Mechanisms of Blood Pressure Regulation. Birkhauser, Boston Basel Berlin, 1992, pp 356-374.
56. Head GA: Cardiac baroreflexes and hypertension. Clin Exp Pharmacol Physiol 1994;21:791-802.
57. Fei L, Anderson MH, Katritsis D, Sneddon J, Statters DJ, Malik M, Camm AJ: Decreased heart rate variability in survivors of sudden cardiac death not associated with coronary artery disease. Br Heart J 1994;71:16-21.
58. Farrell TG, Bashir Y, Cripps T, Malik M, Ploonieeki J, Bennett ED, Ward DE, Canon AJ: Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991;18:687-697.
59. Parati G, Ravogli A, Frattola A, Groppelli A, Ulian L, Santucciu C, Marcia G: Blood pressure variability: clinical implications and effects of antihypertensive treatment. J Hypertens 1994;12(suppl 5):s35-s40.
60. Sannajust F, Head GA: Effect of rilmenidine on the baroreflex control of renal sympathetic nerve activity. J Hypertens 1993;11 (suppl 5):S328-S329.
61. Head GA: Central monoamine systems and new anti-hypertensive agents. Clin Exp Hypertens 1995;17:141-152.
62. Kobinger W: Central α-adrenergic systems as targets for hypotensive drugs. Rev Physiol Biochem Pharmacol 1978;81:39-100.
63. Badoer E, Head GA, Korner PI: Effects of intracisternal and intravenous α-methyldopa and clonidine on haemodynamics and baroreceptor-heart rate reflex properties in conscious rabbits. J Cardiovasc Pharmacol 1983;5:760-767.
64. Godwin SJ, Tortelli CF, Parkin ML, Head GA: Comparison of the baroreceptor-heart rate reflex effects of rilmenidine, moxonidine and clonidine. J Auto Nerv Syst 1998;72:195-204.
65. Isaac L: Clonidine in the central nervous system: site and mechanism of hypotensive action. J Cardiovasc Pharmacol 1980;2:S5-S19.
66. Reis DJ, Granata AR, Joh TH, Ross CA, Ruggiero DA, Park DH: Brainstem catecholamine mechanism in tonic and reflex control of blood pressure. Hypertension 1984;6:7-15.
67. Brody MJ, O'Neill TP, Porter JP: Role of central catecholaminergic systems in pathogenesis and treatment of hypertension. J Cardiovasc Pharmacol 1984;6:S727-S741.
68. Kubo T, Misu Y: Pharmacological characterisation of the α-adrenoceptors responsible for a decrease of blood pressure in the nucleus solitarii of the rat. Naunyn Schmiedebergs Arch Pharmacol 1981;317:120-125.
69. de Jong W, Nijkamp FP: Centrally induced hypotension and bradycardia after administration of α-methylnoradrenaline into the area of the nucleus tractus solitarii of the rat. Br J Pharmacol 1976;58:593-598.
70. Ernsberger P, Feinland G, Meeley MP, Reis DJ: Characterization and visualization of clonidine-sensitive imidazole sites in rat kidney which recognize clonidine-displacing substance. Am J Hypertens 1990;3:90-97.
71. 3H]idazoxan bind to different sites on rabbit forebrain and kidney membranes. Eur J Pharmacol 1988; 146:345-348.
72. Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P: Evidence for the existence of a homogeneous population of imidazoline receptors in the human brainstem. Eur J Pharmacol 1988;150:401-402.
73. Bricca G, Greney H, Zhang JS, Dontenwill M, Stutzmann J, Belcourt A, Bousquet P: Human brain imidazoline receptors: further characterization with [3H]clonidine. Eur J Pharmacol Mol Pharmacol 1994; 266:25-33.
74. 2-adrenoceptors in the human central nervous system. Neuroscience 1994;59: 589-598.
75. Punnen S, Urbanski R, Krieger AJ, Sapru HN: Ventrolateral medullary pressor area: site of hypertensive action of clonidine. Brain Res 1987;422:336-346.
76. Gatti PJ, Hill KJ, Da Silva AMT, Norman WP, Gillis RA: Central nervous system site of action for the hypotensive effect of clonidine in the cat. J Pharmacol Exp Ther 1988;245:373-380.
77. Li YW, Dampney RAL: Clonidine and rilmenidine suppress hypotension-induced fos expression in the lower brainstem of the conscious rabbit. Neuroscience 1995; 66:391-402.
78. Macrae IM, Browne SE: Brain structures involved in the hypotensive effects of rilmenidine: evaluation by [c-14]2-deoxyglucose autoradiography. J Cardiovasc Pharmacol 1995;26:S55-S58.
79. Sannajust F, Barres C, Koenig-Berard E, Sassard J: Sympathoinhibitory effects of rilmenidine may be mediated by sites located below the brainstem. Br J Pharmacol 1992;105:535-541.
80. Sannajust F, Head GA: Involvement of imidazoline-preferring receptors in regulation of sympathetic tone. Am J Cardiol 1994;74 (suppl 13):7A-19A.
81. Head GA, Burke SL: Relative importance of medullary brain nuclei for the sympatho-ihhibitory actions of rilmenidine in the anaesthetised rabbit. J Hypertens 1998; 16:503-517.
82. Stornetta RL, Huangfu D, Rosin DL, Lynch KR, Guyenet PG: Alpha-2 adrenergic receptors: Immunohistochemical localization and role in mediating inhibition of adrenergic RVLM presympathetic neurons by catecholamines and clonidine, in Reis DJ, Bousquet P, Parini A (eds): The Imidazoline Receptor Pharmacology, Functions, Ligands, and Relevance to Biology and Medicine. The New York Academy of Sciences, New York 1995, pp 541-551.
83. Folkow B: Physiological aspects of primary hypertension. Physiol Rev 1982;62:347-504.
84. Koepke JP, DiBona GF: Central adrenergic receptor control of renal function in conscious hypertensive rats. Hypertension 1986;8:133-141.
85. Blanc J, Grichois ML, Vincent M, Elghozi JL: Spectral analysis of blood pressure and heart rate variability in response to stress from air-jet in the Lyon rat. J Auton Pharmacol 1994;14:37-48.
86. Panfilov V, Morris AD, Donnelly R, Reid JL: Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension. J Cardiovasc Pharmacol 1995;26:S44-S47.
87. Burke SL, Malpas SC, Head GA: Effect of rilmenidine on cardiovascular responses to stress in the conscious rabbit. J Auto Nerv Syst 1998;72:177-186.
88. Head GA, Burke SL, Chan CKS: Central imidazoline receptors and centrally acting anti-hypertensive agents. Clin Exp Hypertens 1997;19:591-605.